CRT 2026

IS DCB A CHANGE IN PARADIGM FOR COMPLEX PCI? A CASE-BASED DISCUSSION

Moderator(s)

• 

  Ricardo A. Costa, MD, PhD

  Interventional Cardiologist - Percutaneous Intervention Research Medical Section Chief
  Institute Dante Pazzanese of Cardiology
  Sao Paulo, Sao Paulo, Brazil

  Disclosure(s): No financial relationships to disclose
• 

  Matthew J. Price, MD

  Director, Cardiac Catheterization Laboratory
  Scripps
  La Jolla, California, United States

  Disclosure information not submitted.

Panel Discussant(s)

• 

  Yiannis S. Chatzizisis, MD, PhD

  Professor and Chief, Division of Cardiovascular Medicine
  University of Miami
  Miami, Florida, United States

  Disclosure(s): Boston Scietific: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); medtronic.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)
• 

  Bernardo Cortese, MD, FESC, FSCAI

  Director of Coronary Program
  University Hospitals
  Cleveland, Ohio, United States

  Disclosure(s): Abbott Vascular,: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)